+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.

Age: 18Years +All GendersPhase 1
13 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the effect of fisetin, a natural substance found in strawberries and other foods, on physical function in postmenopausal women who have received chemotherapy for stage I-III breast cancer. This phase II trial focuses on whether fisetin can help improve physical function by eliminating senescent cells that accumulate after chemotherapy, which may cause inflammation and damage to healthy cells. Participants are randomly assigned to receive either fisetin or a placebo orally on days 1, 2, and 3, repeated every two weeks for up to eight weeks, unless disease progression or unacceptable side effects occur. Blood samples are collected throughout the trial to study various biological markers. After treatment, participants are followed yearly for up to three years to monitor long-term outcomes. During the study, participants undergo assessments of physical function such as the 6-minute walk distance, grip strength, and frailty measures. Researchers also evaluate fatigue, neuropathy, cognitive function, quality of life, sleep, anxiety, and depression. Safety and adherence to the study treatment are monitored through patient reports and diaries. The study tracks recurrence-free survival and overall survival over three years, aiming to better understand how fisetin affects health after chemotherapy.

All AgesFEMALEPhase 2
7 locations
U

Actively Recruiting

Researchers are evaluating whether using GPS tracking can improve medication adherence among patients diagnosed with Hepatitis C virus infection who are also experiencing unsheltered homelessness and receiving care through street medicine. This study compares standard medical care for Hepatitis C alone versus standard care combined with GPS tracking to help locate and follow up with patients. The study addresses challenges in traditional healthcare models for homeless populations and aims to explore patient perspectives on GPS tracking in treatment. Participants are randomly assigned to one of two groups one receives the standard Hepatitis C treatment provided through street medicine, while the other receives the same standard treatment plus a GPS tracker device. The GPS device is intended to assist healthcare providers in locating patients for follow-up care during the 8 to 12 weeks of daily medication treatment. This multi-site randomized controlled study includes individual interviews to understand patient experiences in both groups. During the study, participants will be monitored for medication adherence over 8 to 12 weeks, with treatment length also recorded. Researchers will assess sustained virologic response up to about 24 weeks through the study completion. Participants will receive regular street medicine care, and their medication use will be tracked. The study ensures ethical use of GPS tracking and does not involve initial HCV screening, which occurs before enrollment. The total participation time varies with the treatment course and follow-up.

Age: 18Years +All GendersPhase Not Applicable
2 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are evaluating how fisetin, a natural substance found in strawberries and available as a supplement, combined with exercise, may help prevent frailty in postmenopausal breast cancer survivors who have completed chemotherapy. Frailty is a concern because aging cells called senescent cells can cause inflammation and harm healthy tissues. This phase II trial aims to see if fisetin and exercise improve physical function and other health measures in this group. Participants are randomly assigned to one of four groups fisetin with exercise, fisetin with a physical activity handout, placebo with exercise, or placebo with a physical activity handout. Fisetin or placebo is taken orally on days 1-3 of every 14-day cycle for 8 cycles, while exercise groups receive supervised aerobic and resistance training three times a week for 16 weeks. Blood samples are collected during the study. Participants are assessed for changes in physical function using tests like the 6-minute walk distance, grip strength, fatigue levels, neuropathy symptoms, cognition, and quality of life from baseline to day 120. Safety and adherence to treatments are monitored, and participants are followed up at days 120 and 180, then annually for up to three years to track survival and recurrence outcomes.

All AgesFEMALEPhase 2
6 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 for adults with locally advanced or metastatic urothelial cancer, a type of bladder cancer that has spread to nearby tissues or other parts of the body. The study aims to evaluate the safety, effectiveness, and behavior of PF-08634404 in the body, as well as how it affects cancer-related markers. This trial includes adults aged 18 and older who have this type of cancer. The study has two groups Cohort A includes participants who have already received treatment and will receive PF-08634404 alone. Cohort B includes participants who have not had prior treatment and will receive PF-08634404 combined with another cancer medicine called enfortumab vedotin. Both treatments are given through intravenous infusion. Treatment continues as long as it benefits the participant and side effects are manageable. Participants will undergo a screening period to confirm eligibility before starting treatment. During the study, they will have regular visits for treatment, health assessments, scans to monitor cancer progress, and laboratory tests. Researchers will measure outcomes such as the cancers response to treatment, side effects, survival, and drug levels in the body. If the cancer worsens but treatment remains helpful and tolerable, participants may continue treatment with agreement from their doctor and the sponsor. The study follows participants for up to approximately three years.

Age: 18Years +All GendersPhase 1Phase 2
184 locations
S

Actively Recruiting

Researchers are evaluating a new medicine called PF-08634404 in adults with advanced Renal Cell Carcinoma RCC, a type of kidney cancer that has spread locally or to other parts of the body. This study aims to assess the safety of PF-08634404 given alone or combined with other anticancer drugs and to observe how the cancer responds. Participants must be adults with locally advanced or metastatic RCC who have not received treatment for advanced kidney cancer before joining. Participants will be randomly assigned to receive one of four treatments PF-08634404 alone, PF-08634404 with ipilimumab, PF-08634404 with axitinib, or PF-08634404 with Casdatifan. All medications are administered through intravenous infusions or tablets as appropriate, given at clinical study sites by trained medical staff. The study includes treatment and evaluation phases lasting up to approximately three years. During the study, participants will have regular assessments including scans following RECIST v1.1 guidelines to measure tumor response. Researchers will monitor treatment safety by tracking adverse events, dose-limiting toxicities, and laboratory test results. Pharmacokinetics and immune response to the study drug will also be evaluated. These measures will continue through treatment and up to 90 days after the last intervention, with follow-up for up to three years to assess overall survival and progression-free survival.

Age: 18Years +All GendersPhase 1Phase 2
183 locations
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations